Literature DB >> 7543775

Synergistic inhibition of HIV-1 reverse transcriptase DNA polymerase activity and virus replication in vitro by combinations of carboxanilide nonnucleoside compounds.

R S Fletcher1, D Arion, G Borkow, M A Wainberg, G I Dmitrienko, M A Parniak.   

Abstract

The carboxanilides UC84 and UC38 are nonnucleoside inhibitors of both the RNA-dependent and DNA-dependent DNA polymerase activities of HIV-1 reverse transcriptase (RT). We have previously shown that UC84 and UC38 bind to the same site as nevirapine but interact with different RT mechanistic forms, with UC84 preferentially binding to the RT-primer/template complex and UC38 binding only to the RT-primer/template-dNTP ternary complex [Fletcher, R. S., et al. (1995) Biochemistry 34, 4346-4353]. Here we demonstrate that combinations of UC84 and UC38 inhibit RT DNA polymerase activity in vitro in a synergistic manner. This synergy was noted primarily in reactions containing high concentrations of primer/template and Km levels of dNTP substrate and was independent of both primer/template identity and the molar ratio of UC84:UC38. Combination indices were in the range of 0.4-0.6, indicating substantial synergy in the inhibition of RT activity. More importantly, combinations of UC84 and UC38 also showed a high degree of synergy in inhibiting HIV-1 replication in both MT-4 and cord blood mononuclear cells. We believe this to be the first example of synergistic inhibition of HIV-1 RT by combinations of structurally related nonnucleoside inhibitors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7543775     DOI: 10.1021/bi00032a002

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  Analysis of the combined effect of two linear inhibitors on a single enzyme.

Authors:  J J Martinez-Irujo; M L Villahermosa; J Mercapide; J F Cabodevilla; E Santiago
Journal:  Biochem J       Date:  1998-02-01       Impact factor: 3.857

2.  Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and d- and L-(beta)-dideoxynucleoside triphosphate analogs.

Authors:  G Maga; U Hübscher; M Pregnolato; D Ubiali; G Gosselin; S Spadari
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

3.  Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase.

Authors:  G Borkow; J Barnard; T M Nguyen; A Belmonte; M A Wainberg; M A Parniak
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

4.  A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors.

Authors:  Dimitrios Motakis; Michael A Parniak
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

5.  Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates.

Authors:  R W Buckheit; M J Snow; V Fliakas-Boltz; T L Kinjerski; J D Russell; L A Pallansch; W G Brouwer; S S Yang
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

6.  In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1.

Authors:  Mohammad M Hossain; Michael A Parniak
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

7.  Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide.

Authors:  R W Buckheit; T L Kinjerski; V Fliakas-Boltz; J D Russell; T L Stup; L A Pallansch; W G Brouwer; D C Dao; W A Harrison; R J Schultz
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.